FDA Approved: ELAHERE — Supplemental Application (ImmunoGen, Inc.)

View source ↗

Summary

FDA approves a supplemental application for ELAHERE (mirvetuximab soravtansine) from ImmunoGen, Inc. The approval updates the labeling to reflect the approved c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Elahere (mirvetuximab soravtansine)

Snippet

SUPPL AP for ELAHERE (MIRVETUXIMAB SORAVTANSINE)